{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-037619","form_type":"8-K","ticker":"UPB","cik":"0002022626","company_name":"Upstream Bio, Inc.","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.812929+00:00","generated_at":"2026-05-24T22:49:33.657762+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Upstream Bio posts Q4 net loss $21.2M; CRSwNP Ph2 enrollment complete; cash through 2027","bullets":["Net loss of $21.2M in Q4 2024 ($11.8M in Q4 2023); R&D expenses $21.8M vs $11.6M.","Completed enrollment in Phase 2 CRSwNP trial of verekitug; top-line data expected H2 2025.","Cash, equivalents and investments $470.5M as of Dec 31, 2024, funded by upsized IPO ($293M gross).","Phase 2 severe asthma data expected H2 2026; first COPD patient dosing on track for H2 2025.","Appointed Daniella Beckman to Board and Allison Ambrose as General Counsel in late 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-037619","json":"https://secwatch.observer/filing/0000950170-25-037619.json","markdown":"https://secwatch.observer/filing/0000950170-25-037619.md","text":"https://secwatch.observer/filing/0000950170-25-037619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022626/000095017025037619/0000950170-25-037619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022626/000095017025037619/upb-20250312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T22:49:33.657762+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}